PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: However, CIN is also a cell cycle vulnerability that can be exploited to specifically target tumour cells, illustrated by the success of PARP inhibitors to target homologous recombination deficiency (HRD).